Pathological evaluation is the gold standard for identifying processes related to multiple
sclerosis that explain disease manifestations, and for guiding the development of new treatments…

Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured
not only in cerebrospinal fluid but also in serum, which allows for repeated assessments. …

The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple
Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple …

White matter lesions progress over time, but the clinical consequences are widely unknown.
Three‐hundred twenty‐nine elderly community‐dwelling volunteers underwent serial …

In patients with multiple sclerosis (MS), grey matter damage is widespread and might underlie
many of the clinical symptoms, especially cognitive impairment. This relation between …

Cognitive decline is recognized as a prevalent and debilitating symptom of multiple sclerosis
(MS), especially deficits in episodic memory and processing speed. The field aims to (1) …

Objectives: To determine the rate of brain atrophy in neurologically asymptomatic elderly and
to investigate the impact of baseline variables including conventional cerebrovascular risk …

Background and objective: We explored which clinical and biochemical variables predict
conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS…

Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with …

Objective To determine whether brain atrophy and lesion volumes predict subsequent 10
year clinical evolution in multiple sclerosis (MS). Design From eight MAGNIMS (MAGNetic …